Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm	Recruiting	Phase 2	2026-08-17		NCT07673367

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Merck Sharp & Dohme LLC	650
Vanderbilt-Ingram Cancer Center	42

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Vanderbilt University/Ingram Cancer Center	Nashville	United States	12

Clinical trials